FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
More from Archive
More from Pink Sheet
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.